Literature DB >> 27565273

On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?

Laura Vallejo-Torres1, Borja García-Lorenzo2, Iván Castilla3, Cristina Valcárcel-Nazco4, Lidia García-Pérez4, Renata Linertová4, Elena Polentinos-Castro5, Pedro Serrano-Aguilar6.   

Abstract

BACKGROUND: Many health care systems claim to incorporate the cost-effectiveness criterion in their investment decisions. Information on the system's willingness to pay per effectiveness unit, normally measured as quality-adjusted life-years (QALYs), however, is not available in most countries. This is partly because of the controversy that remains around the use of a cost-effectiveness threshold, about what the threshold ought to represent, and about the appropriate methodology to arrive at a threshold value.
OBJECTIVES: The aim of this article was to identify and critically appraise the conceptual perspectives and methodologies used to date to estimate the cost-effectiveness threshold.
METHODS: We provided an in-depth discussion of different conceptual views and undertook a systematic review of empirical analyses. Identified studies were categorized into the two main conceptual perspectives that argue that the threshold should reflect 1) the value that society places on a QALY and 2) the opportunity cost of investment to the system given budget constraints.
RESULTS: These studies showed different underpinning assumptions, strengths, and limitations, which are highlighted and discussed. Furthermore, this review allowed us to compare the cost-effectiveness threshold estimates derived from different types of studies. We found that thresholds based on society's valuation of a QALY are generally larger than thresholds resulting from estimating the opportunity cost to the health care system.
CONCLUSIONS: This implies that some interventions with positive social net benefits, as informed by individuals' preferences, might not be an appropriate use of resources under fixed budget constraints.
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Keywords:  cost-effectiveness analysis; quality-adjusted life-year; threshold

Mesh:

Year:  2016        PMID: 27565273     DOI: 10.1016/j.jval.2016.02.020

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  30 in total

1.  How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13.

Authors:  Stephen Martin; James Lomas; Karl Claxton; Francesco Longo
Journal:  Appl Health Econ Health Policy       Date:  2021-07-21       Impact factor: 2.561

Review 2.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

3.  The societal monetary value of a QALY associated with EQ-5D-3L health gains.

Authors:  Laura Vallejo-Torres; Borja García-Lorenzo; Oliver Rivero-Arias; José Luis Pinto-Prades
Journal:  Eur J Health Econ       Date:  2019-11-28

4.  The Cost-Effectiveness of Adjunctive Lifestyle Interventions for the Management of Cancer: A Systematic Review.

Authors:  Andrew Gallagher; Violetta Shersher; Duncan Mortimer; Helen Truby; Terry Haines
Journal:  Appl Health Econ Health Policy       Date:  2022-09-27       Impact factor: 3.686

5.  Supporting a review of the benefits package of the National Health Insurance Scheme in Ghana.

Authors:  Heleen Vellekoop; Emmanuel Odame; Jessica Ochalek
Journal:  Cost Eff Resour Alloc       Date:  2022-07-16

6.  Value-based drug pricing in the Biden era: Opportunities and prospects.

Authors:  Peter J Neumann; Daniel A Ollendorf; Joshua T Cohen
Journal:  Health Serv Res       Date:  2021-06-03       Impact factor: 3.734

7.  Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver-kidney Transplant as a Case Example.

Authors:  Xingxing S Cheng; Jeremy Goldhaber-Fiebert; Jane C Tan; Glenn M Chertow; W Ray Kim; Anji E Wall
Journal:  Transplantation       Date:  2020-02       Impact factor: 5.385

8.  Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity.

Authors:  A Mavrodi; V Aletras; A Spanou; D Niakas
Journal:  Pharmacoecon Open       Date:  2017-12

9.  Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multi-center, three-armed randomized controlled trial conducted in primary care.

Authors:  Pablo Romero-Sanchiz; Raquel Nogueira-Arjona; Antonio García-Ruiz; Juan V Luciano; Javier García Campayo; Margalida Gili; Cristina Botella; Rosa Baños; Adoración Castro; Yolanda López-Del-Hoyo; Mª Ángeles Pérez Ara; Marta Modrego-Alarcón; Fermín Mayoral Cleríes
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

10.  Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.

Authors:  Marta Trapero-Bertran; Celia Muñoz; Kathryn Coyle; Doug Coyle; Adam Lester-George; Reiner Leidl; Bertalan Németh; Kei-Long Cheung; Subhash Pokhrel; Ángel Lopez-Nicolás
Journal:  Addiction       Date:  2018-03-13       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.